Table 4.
Serum markers of bone turnover
| Parameter | Study treatment | |||||
|---|---|---|---|---|---|---|
| Control (n = 16) | SrRan (n = 16) | SrRan + AD3 (n = 16) | ||||
| Pre-therapy | Post-therapy | Pre-therapy | Post-therapy | Pre-therapy | Post-therapy | |
| β-CrossLaps (ng/ml, mean ± SD) | 0.500 ± 0.16 | 0.482 ± 0.16 | 0.481 ± 0.16 | 0.384 ± 0.11 | 0.472 ± 0.04 | 0.292 ± 0.03 |
| P = 0.30 | P = 0.04 | P < 0.0001 | ||||
| P c = 0.03 | P c < 0.001 | |||||
| P SR = 0.008 | ||||||
| Median (IQR) | 0.496 (0.387–0.619) | 0.470 (0.369–0.598) | 0.480 (0.370–0.539) | 0.421 (0.294–0.432) | 0.476 (0.439–0.491) | 0.302 (0.261–0.314) |
| % Change (↓ ↑) | 3.54 ↓ | 18.7 ↓ | 37.7 ↓ | |||
| TP1NP (ng/nl, mean ± SD) | 0.294 ± 0.06 | 0.304 ± 0.11 | 0.304 ± 0.07 | 0.414 ± 0.10 | 0.304 ± 0.07 | 0.458 ± 0.11 |
| P = 0.42 | P < 0.0001 | P < 0.0001 | ||||
| P c = 0.001 | P c < 0.001 | |||||
| P SR = 0.10 | ||||||
| Median (IQR) | 0.272 (0.254–0.324) | 0.274 (0.242–0.336) | 0.279 (0.261–0.327) | 0.391 (0.354–0.451) | 0.278 (0.260–0.324) | 0.433 (0.383–0.508) |
| % Change (↓ ↑) | 3.74 ↑ | 35.9 ↑ | 51.4 ↑ | |||
| PTH (pg/ml, mean ± SD) | 68.2 ± 14.5 | 66.7 ± 14.5 | 69.4 ± 7.69 | 65.4 ± 8.35 | 71.1 ± 9.53 | 64.6 ± 9.74 |
| P = 0.16 | P = 0.17 | P = 0.03 | ||||
| P c = 0.28 | ||||||
| P SR = 0.46 | ||||||
| Median (IQR) | 66.7 (62.7–80.7) | 64.9 (60.2–79.7) | 68.6 (63.4–72.9) | 65.1 (59.4–69.2) | 71.7 (63.4–75.6) | 62.9 (60.2–67.9) |
| % Change (↓ ↑) | 2.26 ↓ | 5.84 ↓ | 9.29 ↓ | |||
AD 3 alfacalcidol, IQR interquartile range (25th–75th percentiles), P compared with parameter before therapy, P c compared with parameter in the control group, P SR compared with parameter in SrRan group after therapy, PTH parathyroid hormone, SD standard deviation, SrRan strontium ranelate, TP1NP type 1 procollagen total N-terminal propeptide